A B S T R A C T Properdin deposition has been recognized in glomeruli of patients with acute and chronic nephritis and lupus nephritis, and low serum properdin levels have been found in these disorders. These findings suggest that properdin may be involved in the production of glomerular damage and that low properdin levels may be due to hypercatabolism. The study was designed to examine the metabolism of properdin in normal subjects and to look for an abnormality in five patients with systemic lupus erythematosus with renal involvement and in six patients with membranoproliferative glomerulonephritis or dense deposit disease (MPGN).
INTRODUCTION
The properdin system or alternative pathway of complement activation was first described by Pillemer et al.
in 1954 (1) , and it has subsequently been shown that one of its components, properdin, is a 5.2S glycoprotein of mol wt 184,000 (2) . Despite the demonstration almost 20 yr ago that properdin participates in a nonspecific natural defense mechanism, no clear understanding of the specific function of this molecule has been reached, and its precise physiological role remains to be discovered. There is some indirect evidence, however, that properdin may be involved in the pathogenesis of certain forms of renal disease: properdin levels have been found to be low in acute glomerulonephritis, membranoproliferative glomerulonephritis or dense deposit disease (MPGN)' (3), and in systemic lupus erythematosus (SLE) nephritis (4) (5) (6) . Immunofluorescent studies have demonstrated properdin in glomeruli in acute and chronic nephritis (7) and in SLE nephritis (6) . To (10) . To explain the changes in properdin levels, a properdin metabolic study was also performed in this patient. METHODS Subjects. Members of the hospital staff served as controls. Five patients with SLE nephritis and six with MPGN were studied, and a summary of their pertinent clinical data is given in Table I . Properdin metabolism was also studied in the patient with a hereditary KAF deficiency.
Preparation of ..I-labeled properdin. Properdin was isolated as previously described (11) and found to be free of pyrogenic activity and hepatitis-associated antigen. It was labeled with 'I by the iodine monochloride method (12) and sterilized by Millipore filtration (Millipore Corp., Bedford, Mass.) after extensive dialysis against phosphatebuffered saline to remove free label. 1% human serum albumin was added to prevent autoirradiation and non-7__ -_ specific adsorption to glass, and the labeled properdin was properties of the properdin preparation were determined UME FROM BOTTOM OF TUBE (ml) at described (11) and by zymosan uptake of labeled properdin in the presence of normal serum (13) . r of purified properdin by sucrose density Administration of ...I-properdin. Each subject received ntrifugation. 0.5 ml of purified protein at 1-2 uCi of 'I-properdin intravenously after blockade of of 25 ,ug/ml in phosphate buffered saline thyroidal iodine uptake with potassium iodide. Exactamount I with 0.5%o bovine serum albumin, was of radioactivity administered was determined by measuring -ml 1040% linear sucrose density gradient the weight of material injected and assaying a small Lnd centrifuged at 41,000 rpm for 26 h at sample of the dose for radioactivity.
were monitored for properdin by radioimCollection and analysis of samples. Blood was drawn rkers used were thyroglobulin (19.2S), into EDTA at 10 min after the injection and at frequent lobulin (BGG,7.3S), andovalbumin (3.5S). intervals thereafter for 5-6 days. Red cells and plasma were separated by centrifugation, and radioactivity of plasma was assayed in a Packard gamma scintillation counter (Packard Instrument Co., Inc., Downers Grove, Ill.). Washed red cells in several patient and control studies were regularly found to be free of radioactivity, so this procedure was dropped from the protocol. Urine was collected throughout the studies, and total radioactivity determined for each sample. Comparison of whole plasma radioactivity and trichloroacetic acid (TCA)-precipitable radioactivity showed no significant difference in results even in patients with impaired renal function, so that only data of whole plasma radioactivity have been analyzed in detail.
Similarly, TCA-precipitable radioactivity in urine was negligible even in the presence of gross unselective proteinuria.
Serum protein quantitation. Plasma samples obtained at the beginning, middle, and end of the study were assayed for properdin by electroimmunoassay (14) with a monospecific rabbit antiserum. Plasma levels of properdin factor B, C4, C3, and C5 were also measured by electroimmunoassay.
Calculation of parameters of metabolism. The Matthews method (15) was used to calculate (a) the catabolic rate of properdin as the fraction of the plasma pool catabolized per hour (FCR), (b) the synthetic rate as micrograms of properdin per kilogram per hour, and (c) the extravascular pool to plasma pool ratio. A second estimation of FCR (Campbell, Cuthbertson, Matthews, and McFarlane, 16) was obtained by plotting the ratio of urinary excretion of label to the mean plasma radioactivity during the time of production of each urine sample on the ordinate versus time on the abscissa. FCR and pool ratios were also determined by the method of Nosslin (17) , who has shown that the plots of 1-PIE and of fJttiEdt/E (ordinate) against fJtiPdt/E (abscissa) are straight lines, the slopes of which are the FCR and extravascular to plasma pool ratio, respectively. (P is the plasma pool, and E is the extravascular pool at time t; E is given by 1-U-P where U is cumulative urinary radioactivity.) RESULTS
The properdin preparation used in this study was in all respects identical physicochemically and functionally to that prepared by Pensky et al. (11) . It contained no material which would enter an alkaline disc gel. Continuous sucrose density gradient ultracentrifugation of the purified properdin showed it to be homogeneous and free of high molecular weight aggregates (Fig. 1) . Autoradiography of 'I-labeled properdin after agarose gel electrophoresis in 0.05 M veronal buffer, pH 8.6, showed a single band of radioactivity at the origin (Fig. 2) . When labeled properdin was incubated with zymosan in the presence of normal human serum at 370C (13), up to 60% of the label was taken up by zymosan.
In all five patients with SLE, properdin disappeared more rapidly from the plasma pool than in the control subjects (Fig. 3) . In three of the six patients with MPGN, properdin was also hypercatabolized (Fig. 4) .
Results of immunochemical determinations of properdin, C3, C4, C5, and factor B are shown in Table  II . C3 levels were reduced in five of the six patients Campbell and Nosslin. (Urine collections were incomplete for P. M., as well as for two control subjects, so that only Matthews analysis is possible in these cases.)
In the present study, properdin metabolism has been found to differ from that usually seen with other serum proteins. In general, the semilog plots of total body, plasma, and extravascular radioactivity become parallel as equilibration throughout all compartments is colupleted and final exponentials are adopted (18) . The extravascular pool of radiolabeled properdin, however, reached an optimal value of between 20 and 50% of the injected dose, and then maintained this value throughout most of the duration of the study (see Fig. 5 ). This was seen in patients as well as controls and representative cases are shown in the figure.
The extravascular to plasma pool ratio as calculated by the Matthews method ranged from 0.15 to 0.54 in control subjects, and values in the patients were generally within this range (Table III) activity data, indicated higher extravascular pools in all studies, the highest ratios occurring in patients with high FCR. A properdin metabolic study was performed in the patient with KAF deficiency, and the plasma radioactivity decay curve and FCR were normal. This analysis indicated that the low properdin level in this patient is due to decreased synthesis (2.9 iug/kg per h).
DISCUS SION The FCR of properdin in normal subjects was found to be only about 1% of the plasma pool/h, about half that found for C3 (19) and factor B (20) . It is probable that properdin catabolism in normal subjects is largely a result of a general catabolic process, and it does not appear necessary to assume that activation or utilization is an important factor in properdin metabolism in health. It should be pointed out, however, that if activation or degradation products of properdin had the same plasma half-life as the parent molecule, the change in state during activation would not be reflected in plasma radioactivity levels (19) .
Rapid properdin catabolism has been shown in this study to be a feature of two diseases in which localization of properdin in affected tissues has been demonstrated (6, 7). It seems likely, therefore, that as a result of the pathological process in these disorders, up to 1.3% of the plasma pool of properdin is catabolized hourly, in addition to 1%/h subject to a general catabolic process.
FCR's calculated by the Functional heterogeneity of purified properdin might explain the extravascular sequestration of up to half the injected material. It is possible that properdin in one functional state remains in equilibrium with the plasma pool and is subject to normal and pathological fates of native properdin; a second form may represent a molecule functionally altered so that it is sequestrated, perhaps in the reticuloendothelial system, and its catabolism is therefore delayed.
There was no correlation between properdin metabolism and renal pathology in this small group of patients, but the three MPGN patients with the longest disease duration had normal properdin FCR, suggesting that properdin hypercatabolism may be a feature predominantly of early disease.
This study has shown significant abnormality in properdin metabolism in SLE nephritis and MPGN and shows that hypercatabolism alone and not hyposynthesis explains earlier reports of low properdin levels. Renal hypercatabolism of properdin would be consistent with the demonstration of glomerular deposition. (6) , it is possible that these contain complexes of C3 and properdin formed in vivo. It is not clear whether, if this is the case, the glomerular material represents deposition of properdin-C3 complexes formed in the circulation sequestered in the glomeruli or whether one of these proteins is deposited primarily, with complex formation following. Nor is it possible to say whether this process is a cause or a consequence of glomerular damage. An altered state of the protein may at least partly explain unusual features of its metabolism in normal subjects.
